A Timeline of US Biosimilar Adalimumab Launch Dates

AbbVie has struck agreements with multiple developers over biosimilar adalimumab, forestalling US market entry until 2023. Here's when each product could potentially reach US patients.

Related Content:

BusinessRheumatology

Tocilizumab Biosimilar CT-P47 Shows Promise for Rheumatoid Arthritis Self-Administration

FDA Approves Steqeyma for Children With Plaque Psoriasis, Psoriatic Arthritis

Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan